Home > Insider Trading > Filing (0001354488-12-006165)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1024126	Pernix Therapeutics Holdings Inc.	PTX	Pharmaceutical Preparations (2834)	330724736

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1413616	Cooper Michael Pearce	10003 Woodloch Forest Drive #950 The Woodlands TX 77380		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-11-20	17,242	$4.20	53,909	No	4	M	Direct
Common Stock	Disposition	2012-11-20	17,242	$7.23	36,667	No	4	S	Direct
Common Stock	Acquisiton	2012-11-21	3,440	$4.20	40,107	No	4	M	Direct
Common Stock	Disposition	2012-11-21	3,440	$7.37	36,667	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2012-11-20	17,242	$0.00	17,242	$4.20
Common Stock	Employee Stock Option (right to buy)	Disposition	2012-11-21	3,440	$0.00	3,440	$4.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
47,740		2013-03-09	No	4	M	Direct
44,300		2013-03-09	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/16/12.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.01 to $7.35, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.28 to $7.41, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option which represents a right to purchase a total of 137,500 shares of which 72,518 were purchased prior to 11/20/2012 date, became fully exercisable on 3/9/10.